Ralph V. Boccia, MD

home / authors / ralph-v-boccia-md

Ralph V. Boccia, MD, is the founder of The Center for Cancer and Blood Disorders and board-certified in medical oncology, hematology and internal medicine.

Articles

mCSPC: Incorporating Newer Therapies Into Practice

mCSPC: Incorporating Newer Therapies Into Practice

Ralph V. Boccia, MD
December 2nd 2020
AR-Targeted Therapy for mCSPC: Monitoring for Progression

AR-Targeted Therapy for mCSPC: Monitoring for Progression

Ralph V. Boccia, MD
December 2nd 2020
AR-Targeted Therapy for mCSPC: Adverse Events

AR-Targeted Therapy for mCSPC: Adverse Events

Ralph V. Boccia, MD
December 2nd 2020
The TITAN Trial in mCSPC

The TITAN Trial in mCSPC

Ralph V. Boccia, MD
December 2nd 2020
mCSPC: Patient Variables and Treatment Selection

mCSPC: Patient Variables and Treatment Selection

Ralph V. Boccia, MD
December 2nd 2020
Frontline Therapy for mCSPC

Frontline Therapy for mCSPC

Ralph V. Boccia, MD
December 2nd 2020
Case Impressions: 66-Year-Old Man With mCSPC

Case Impressions: 66-Year-Old Man With mCSPC

Ralph V. Boccia, MD
December 2nd 2020
A 66-Year-Old Man With Metastatic Castrate-Sensitive Prostate Cancer

A 66-Year-Old Man With Metastatic Castrate-Sensitive Prostate Cancer

Ralph V. Boccia, MD
December 2nd 2020

Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.

Latest Updated Articles

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Innovative ctDNA Testing Drives Progress in NSCLC Research
Published: November 20th 2024 | Updated: November 23rd 2024
Innovative ctDNA Testing Drives Progress in NSCLC Research
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Published: November 13th 2024 | Updated: November 23rd 2024
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Published: August 18th 2023 | Updated: November 23rd 2024
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Published: October 19th 2024 | Updated: November 23rd 2024
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
Published: June 6th 2024 | Updated: November 23rd 2024
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer